External validation of a heart failure risk score in patients with acute myeloid leukemia

Abstract

A 21-point risk score for heart failure (HF) has been developed for patients with acute myeloid leukemia (AML), stratifying patients into three groups: low, moderate, and high-risk. In this study, 193 patients with AML treated with anthracycline-based therapy were stratified using the risk score, and its prognostic utility for HF events and all-cause mortality at one year of follow-up were evaluated. HF occurred in 18% (34/193) of anthracycline-treated patients. Global longitudinal strain (GLS) was more negative among patients without HF events (−19 ± 3 vs. −17 ± 4%). One year incidence of HF was increased in the higher risk groups: 12% of low-risk, 24% of moderate-risk, and 50% of high-risk (p < 0.001). However, a higher risk score was not associated with an increased risk of all-cause mortality. This study provides external validation of a 21-point risk score for HF events but not all-cause mortality at one year in patients with AML.

Keywords:

• Acute myeloid leukemia
• external validation
• heart failure
• risk score
• global longitudinal strain
• anthracycline chemotherapy

Author contributions

All authors contributed to the study design, data collection and analysis, and creation of the manuscript. All authors meet ICMJE guidelines for authorship in this manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).